Sifting through countless of stocks in the Health Care Providers & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Progyny, Inc., Astrana Health or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Progyny, Inc., Astrana Health and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Progyny, Inc., Astrana Health and Inc.

Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists. The company serves patients primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was founded in 1992 and is headquartered in Alhambra, California.

Latest Health Care Providers & Services and Progyny, Inc., Astrana Health, Inc. Stock News

As of July 31, 2026, Progyny, Inc. had a $2.4 billion market capitalization, compared to the Health Care Providers & Services median of $1.7 million. Progyny, Inc.’s stock is up 21.2% in 2026, down 0.2% in the previous five trading days and up 32.47% in the past year.

Currently, Progyny, Inc.’s price-earnings ratio is 40.7. Progyny, Inc.’s trailing 12-month revenue is $1.3 billion with a 5.2% net profit margin. Year-over-year quarterly sales growth most recently was 1.4%. Analysts expect adjusted earnings to reach $2.057 per share for the current fiscal year. Progyny, Inc. does not currently pay a dividend.

As of July 31, 2026, Astrana Health, Inc. had a $1.6 billion market cap, putting it in the 51st percentile of all stocks. Astrana Health, Inc.’s stock is up 43.3% in 2026, down 11.8% in the previous five trading days and up 47.67% in the past year.

Currently, Astrana Health, Inc.’s price-earnings ratio is 58.4. Astrana Health, Inc.’s trailing 12-month revenue is $3.5 billion with a 0.9% net profit margin. Year-over-year quarterly sales growth most recently was 55.6%. Analysts expect adjusted earnings to reach $2.920 per share for the current fiscal year. Astrana Health, Inc. does not currently pay a dividend.

How We Compare Progyny, Inc., Astrana Health and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Progyny, Inc., Astrana Health and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Progyny, Inc., Astrana Health and Inc. Growth Grades

Company	Ticker	Growth
Progyny, Inc.	PGNY	B
Astrana Health, Inc.	ASTH	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Progyny, Inc. has a Growth Score of 69, which is Strong. Astrana Health, Inc. has a Growth Score of 69, which is Strong.

The Growth Grade Winner: It’s a Tie!

Looking at the Growth Grade breakdown above, both Progyny, Inc., Astrana Health and Inc. have a grade of B. For investors who focus solely on a company’s upward growth, further research should be conducted into both companies’ other financial metrics before deciding whether to invest.

Progyny, Inc., Astrana Health and Inc.’s Momentum Grades

Company	Ticker	Momentum
Progyny, Inc.	PGNY	A
Astrana Health, Inc.	ASTH	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Progyny, Inc. has a Momentum Score of 92, which is Very Strong. Astrana Health, Inc. has a Momentum Score of 78, which is Strong.

The Momentum Grade Winner: Progyny, Inc.

As you can clearly see from the Momentum Grade breakdown above, Progyny, Inc. is considered to have stronger momentum compared to Astrana Health, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Progyny, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Progyny, Inc., Astrana Health and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Progyny, Inc.	PGNY	B
Astrana Health, Inc.	ASTH	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Progyny, Inc. has a Earnings Estimate Score of 69, which is Positive. Astrana Health, Inc. has a Earnings Estimate Score of 55, which is Neutral.

The Earnings Estimate Revisions Grade Winner: Progyny, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Progyny, Inc. has a better Earnings Estimate Revisions Grade than Astrana Health, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Progyny, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Progyny, Inc., Astrana Health and Inc. Grades

In addition to Estimate Revisions, Momentum and Growth, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Progyny, Inc., Astrana Health and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Progyny, Inc., Astrana Health or Inc. Stock?

Overall, Progyny, Inc. stock has a Growth Score of 69, Momentum Score of 92 and Estimate Revisions Score of 69.

Astrana Health, Inc. stock has a Growth Score of 69, Momentum Score of 78 and Estimate Revisions Score of 55.

Comparing Progyny, Inc., Astrana Health and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.